Table 1.

—Baseline Demographic and Clinical Characteristics of Patients With LAM

Characteristic	Value
Age, mean ± SEM, y
At presentation with LAM-related symptoms	36.8 ± 8.6
At diagnosis of LAM symptoms	40.9 ± 8.4
At enrollment in the NHLBI LAM protocol	42.7 ± 8.1
At initiation of sirolimus therapy	47.2 ± 10.0
At most recent follow-up visit	49.7 ± 9.3
Interval from diagnosis to initiation of sirolimus therapy, mean ± SD, y	6.3 ± 6.7
Race
White	20 (87)
African American	1 (4)
Asian	1 (4)
Unknown	1 (4)
Clinical features
Tuberous sclerosis complex	4 (17)
Postmenopausal	9 (39)
History of pneumothorax	7 (30)
History of dyspnea	15 (65)
Requirement for oxygen therapy	9 (39)
Chylous pleural effusions	10 (43)
Ascites	6 (26)
Lymphangioleiomyomas	16 (70)
Lymphadenopathy	6 (26)
Renal angiomyolipoma	7 (30)

Data are presented as No. (%) unless otherwise indicated. LAM = lymphangioleiomyomatosis; NHLBI = National Heart, Lung, and Blood Institute.